Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges

Executive Summary

Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.


Related Content

Bayer To Ship Long-Acting Hemophilia Infusion Jivi In A Jiffy
Spark's Gene Therapy Hemophilia Data Give Investors The Jitters
BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications
Hemlibra Hits The Heights In HAVEN Hemophilia Trials
Bioverativ: More Than Just A Hemophilia Company
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
CSL Looks Beyond Organic Growth To External Innovation
Pharma Justifies Steep Prices, Plans Fancy Footwork In The Era Of Cures
Installment Payments For Gene Therapy; From Luxturna To Hemophilia
The Year's Clinical Trials In Review: Big Hits In 2017


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts